大动脉剖析与脂蛋白 (a) 的关联:一个元分析
Karam R Motawea1, Rowan H Elhalag1, Samah S Rouzan1
1Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Annals of medicine and surgery (2012)
|June 26, 2023
概括
这次元分析发现大动脉剖析 (AD) 与升高的脂蛋白 (a) [LP(a]水平之间存在显著的关联. 在阿尔茨海默病患者中增加的LP (a) 与较低的甘油三,LDL胆固醇和总胆固醇水平相关.
科学领域:
- 心血管科学 心血管科学
- 生物化学 生物化学
- 医学研究 医学研究
背景情况:
- 关于大动脉剖析 (AD) 和脂蛋白 (a) [LP(a) ]水平之间的关系,存在相互矛盾的研究结果.
- 需要进行元分析来澄清AD与升高LP的关联.
研究的目的:
- 进行元分析以确定大动脉解剖 (AD) 与高水平脂蛋白 (a) [LP(a) ]之间的关系.
主要方法:
- 在多个数据库进行了全面的文献搜索,包括PubMed,Scopus,Web of Science,SAGE,EMBASE,Science Direct和Cochrane图书馆.
- 纳入标准侧重于随机对照试验和观察性研究,测量阿尔茨海默病患者和健康对照者的LP (a) 水平,不包括病例报告,评论和动物研究.
- 包含678名患者的四项研究被纳入最终的元分析.
主要成果:
- 综合分析显示,大动脉剖析 (AD) 组与脂蛋白 (a) [LP(a) ]水平增加之间存在统计学上显著的关联.
- 在阿尔茨海默病患者中,升高的LP (a) 与降低甘油三 (TG),低密度脂蛋白胆固醇 (LDL-C) 和总胆固醇 (TC) 的水平同时相关.
- 具体的统计发现包括:MD=11.71 (95%CI=4.11-19.32,P=0.003) 的LP(a);MD=-0.32 (95%CI=-0.48至-0.16,P<0.0001) 的TG;MD=-0.21 (95%CI=-0.42至-0.1,P=0.04) 的LDL-C;和MD=-0.58 (95%CI=-0.62至-0.54,P<0.00001) 的TC.
结论:
- 大动脉解剖 (AD) 与升高的脂蛋白 (a) [LP(a) ]水平有显著的关联.
- 在阿尔茨海默病患者中观察到的LP (a) 增加与甘油三,低密度脂蛋白胆固醇和总胆固醇的减少相关.
- 未来的临床试验研究LP (a) 向疗法可能为高风险个体提供AD的初级或二级预防的潜力.
相关概念视频
Atherosclerosis I: Introduction
13
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
13
Peripheral Artery Disease I: Introduction
11
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
11
Coronary Artery Disease I: Introduction
28
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
28
Aneurysm I: Introduction
16
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
16
Coronary Artery Disease II: Pathophysiology
15
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
15
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15


